News

Clinical Trial Application for Phase I trial of AXL1717 new capsule formulation submitted in India 9 January 2018
Since 2015 Axelar AB has had a co-development agreement with Cadila Pharmaceuticals Ltd for collaboration on AXL1717 formulation development and clinical development. Cadila Pharmaceuticals Ltd has developed a new AXL1717 formulation in 25 & 50 …
Axelar attends BIO-Europe partnering conference in Berlin, Germany 6 November 2017
Axelar AB will attend the 23rd annual BIO-Europe conference in Berlin, Germany on November 6-8, 2017 to meet with potential partners and investors. The BIO-Europe conference is Europe's largest partnering conference serving the global biotechnology …
Axelar attends BIO Investor Forum in San Francisco, USA 17 October 2017
Axelar AB will attend the BIO Investor Forum in San Francisco, USA on October 17-18, 2017 to meet with potential partners and investors. The BIO Investor Forum is an international biotech investor conference focused on early and established private …

Archive